List of Diagnostics Companies in Denmark - 7

At ALK, we go to work every day to make a difference for the many people with allergies around the world. It is our ambition to make life with allergy surprisingly simple for as many people as possible, and we build upon our strong heritage as a pioneer in allergy immunotherapy, when we continue to innovate, develop and market new products and solutions to help improve the health of people with allergies. Every day, our employees contribute to our aspiration of becoming the world leader in allergy by coming to work to do their best in the pursuit of providing new and better allergy treatments and solutions. We work in a high-energy, international setting where it is imperative that our people thrive and develop. Creativity, influence and opportunities are key elements in developing our people. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

ARCEDI Biotech ApS is a Danish biotech company involved in developing technologies for rare cell detection, a widely sought after application in the prenatal as well as cancer diagnostics. ARCEDI Biotech has proprietary method to enrich fetal cells from circulating maternal blood with high efficiency. Once enriched, the fetal cells can be utilized for downstream analysis using technologies such as FISH, 'Next Generation Sequencing', etc.

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark, and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. To learn more about our products and their availability in your country, please visit https://bioporto.com/products/. Posts are not intended for a U.S. audience. If you are from the United States, you are encouraged to visit https://www.linkedin.com/company/bioporto-diagnostics-inc-us/ Social Media Community Guidelines: https://bioporto.com/social-media/

Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. We are targeting the growing need for throughput with robust solutions for clinical and large-scale proteomics, and we have a very ambitious business plan to bring the community closer to the clinic. We are basing our design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis.

Immudex is a pioneering life science company spearheading the global adoption of precision immune monitoring. Since 2009, Immudex has been striving to provide researchers worldwide with reliable tools to monitor the cellular immune response accurately. Our goal is to utilize the complex actions and interactions of the immune system to help researchers better understand the causes, accelerate the diagnosis, and more accurately predict the prognosis of diseases. To that end, Immudex markets prime Dextramer® and dCODE® (DNA-barcoded) MHC multimer technologies that grant researchers and clinicians detailed insights into disease-specific immunity resolved to antigen-specific cell populations and single cells. Additionally, Immudex is mandated by the CIC and CIMT to coordinate yearly evaluations of T-cell immune monitoring proficiency and drive the generation of high-quality data that advance immunotherapies. Research, development, and commercial activities are headquartered in Copenhagen, Denmark, with operations in North America out of Fairfax, Virginia. Find out more at www.immudex.com.

VenomAid Diagnostics is a young, impact-oriented medtech start-up developing affordable, easy-to-use, and robust diagnostics enabling best-in-class snakebite management worldwide, ultimately reducing the global burden of snakebite. Snakebite is a global problem affecting millions of people worldwide, most severely in low- and middle-income countries. The only effective treatment, specific antivenom, is scarcely available and can only be given if the perpetrating snake is known.

Demant is a world-leading hearing healthcare and technology group built on a heritage of care, health and innovation since 1904. The Group offers solutions and services to help people connect and communicate with the world around them. For more than a century, the Demant Group has played a vital part in developing innovative technologies and gathering know-how to help improve people's hearing and health. In every aspect, from providing hearing care to delivering hearing aids, hearing implants and diagnostic equipment and services to hearing care professionals and users all over the world, Demant is active and engaged. And with the Group's many years of experience with audio and hearing technology, Demant has evolved into a growing business within premium audio and video solutions for enterprises and gaming. The Demant Group operates in a global market with subsidiaries in more than 30 countries, employs more than 20,000 employees and generates an annual revenue of more than DKK 19 billion. Our products are sold in more than 130 countries where we create life-changing differences through hearing health. Listed on Nasdaq Copenhagen stock exchange, Demant is the parent company behind world-renowned and commercially successful brands as Oticon, Bernafon, Sonic, Philips Hearing Solutions, Audika, Oticon Medical, MAICO, Interacoustics, Amplivox, Grason-Stadler, MedRx, Audioscan and EPOS. The William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks. If you want to know how we process your personal data on social media platforms, visit this site: https://www.demant.com/privacy-notice#some